Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | DUT | P33316 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | HTR2C | P28335 | 3/20 | 0.35 |
| ▸ | HTR2B | P41595 | 3/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20207598 | 0.88 | SCN9A (0.44) | SCN9AMCHR1DUTHPGD | |
| SCHEMBL1409593 | 0.87 | DUT (0.45) | DUTHTR2AHTR2CHTR2B | |
| SCHEMBL21350429 | 0.81 | SCN9A (0.40) | SCN9ADUTHPGD | |
| SCHEMBL18376335 | 0.79 | SCN9A (0.46) | SCN9AMCHR1HPGD | |
| SCHEMBL20201950 | 0.77 | SCN9A (0.44) | SCN9AMCHR1HPGD | |
| SCHEMBL18374371 | 0.76 | SCN9A (0.42) | SCN9AMCHR1DUTHPGDNFE2L2 | |
| SCHEMBL20373902 | 0.75 | SCN9A (0.43) | SCN9AMCHR1DUT | |
| Hydrochloric Acid SCHEMBL20191182 | 0.75 | SCN9A (0.41) | SCN9AMCHR1DUTHPGDNFE2L2 | |
| Hydrochloric Acid SCHEMBL20191183 | 0.75 | SCN9A (0.41) | SCN9AMCHR1DUTHPGDNFE2L2 | |
| SCHEMBL20347946 | 0.75 | DUT (0.46) | DUTHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570098-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-25 | — | — | US | disclosed |
| US-20180186737-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570098-B2 | Hydantoin containing deoxyuridine triphosphatase inhibitors | DUT, TYMP, DPYD | SCN9A 4663/4885MCHR1 4545/4885DUT 1/4885 |
| US-20180186737-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | SCN9A 4663/4885MCHR1 4545/4885DUT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.